Cargando…
From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy
SIMPLE SUMMARY: Immune control inhibitor drugs (anti-PD1/PD-L1/CTLA-4) (ICIs) are showing efficacy in the treatment of lung cancer. Currently the only biomarker with clinical utility for ICIs, such as the expression of PDL1, does not appear to be perfect or effective. Our working group is conducting...
Autores principales: | Sesma, Andrea, Pardo, Julián, Cruellas, Mara, Gálvez, Eva M., Gascón, Marta, Isla, Dolores, Martínez-Lostao, Luis, Ocáriz, Maitane, Paño, José Ramón, Quílez, Elisa, Ramírez, Ariel, Torres-Ramón, Irene, Yubero, Alfonso, Zapata, María, Lastra, Rodrigo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602200/ https://www.ncbi.nlm.nih.gov/pubmed/33066479 http://dx.doi.org/10.3390/cancers12102974 |
Ejemplares similares
-
Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?
por: Gascón, Marta, et al.
Publicado: (2020) -
Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy
por: Ocáriz-Díez, Maitane, et al.
Publicado: (2020) -
A Subset of PD-1-Expressing CD56(bright) NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer
por: Gascón-Ruiz, Marta, et al.
Publicado: (2023) -
Diagnosis of Malnutrition According to GLIM Criteria Predicts Complications and 6-Month Survival in Cancer Outpatients
por: Gascón-Ruiz, Marta, et al.
Publicado: (2022) -
PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells
por: Pesini, Cecilia, et al.
Publicado: (2022)